Next Treatments
Back to Eczema

afimkibart

TypeInjection StagePhase 2 Latest updateUpdated recently. Jul 22, 2026Phase 2 main data collected

What stands out

New approach in eczema

  • Binds to TL1A, a signal that boosts T-cell activation
Derived from FDA substance registry · UniProt O95150 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Apr 1, 2025. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Jul 22, 2026Phase 2 main data collectedA Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06863961
  • Jan 8, 2026Phase 2 trial startedA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis ClinicalTrials.gov NCT07223697
  • Apr 1, 2025Phase 2 trial startedA Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06863961

Sources

Trials